Market Overview:
The global peripheral neuritis treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, chemotherapy-induced peripheral neuropathy (CIPN), and idiopathic peripheral neuropathy (IPN). In addition, the growing demand for better and more effective treatments for peripheral neuritis is also contributing to the growth of this market. Based on type, the global peripheral neuritis treatment market can be segmented into diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), idiopathic peripheral neuropathy (IPN), and others. DPN is estimated to account for the largest share of this market in 2018 owing to its high prevalence among patients with diabetes mellitus. Based on application, hospital pharmacies are estimated to account for the largest share of this market in 2018 followed by retail pharmacies and online pharmacies. Geographically, North America is estimated to account for the largest share of this market in 2018 followed by Europe, Asia Pacific, Latin America, and Middle East & Africa.
Product Definition:
Peripheral neuritis is a type of nerve damage that affects the peripheral nervous system. The peripheral nervous system includes all the nerves outside of the brain and spinal cord. Peripheral neuritis can cause pain, numbness, tingling, or weakness in the arms and legs. Treatment for peripheral neuritis may include medications to relieve pain and inflammation, physical therapy to improve strength and mobility, and/or surgery if there is permanent damage to the nerves.
Diabetic Peripheral Neuropathy (DPN):
Diabetic Peripheral Neuropathy (DPN) is a neuropathy that affects the peripheral nervous system of patients with diabetes mellitus. The nerve damage in such patients may lead to pain, tingling or shooting pains in the extremities, weakness or numbness in the hands and feet as well as legs, difficulty in using any device like pen & paper, testing equipment etc., slow wound healing and foot problems among other conditions.
Chemotherapy-induced Peripheral Neuropathy (CIPN):
Chemotherapy-induced Peripheral Neuropathy (CIPN) is a condition that affects the peripheral nervous system. The neuropathy can be classified into two types: chemotherapy-induced pure motor neuropathy and chemotherapy-induced sensory neuropathy. Motor neuropathies are rare in comparison to sensory ones; however, both may occur together as they share some commonalities such as muscle twitching, foot drop, and abnormal movements.
Application Insights:
Based on the application, the global peripheral neuropathy treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacy held the largest share of over 60.0% in 2017 owing to factors such as high prevalence of chronic diseases that require regular medication and growing geriatric population with susceptible immune system.
Retail pharmacy is expected to be fastest-growing segment during forecast years due to increasing awareness among people regarding their health and safety along with rising healthcare expenditure in developing countries such as India, China and Brazil.
Regional Analysis:
North America dominated the global peripheral neuropathy treatment market in 2017. The presence of well-developed healthcare infrastructure, high awareness levels amongst patients, and availability of effective treatment for various types of peripheral neuropathies are some factors contributing to its large share. Moreover, rising incidence rates for various causes such as diabetes and obesity are also expected to contribute towards its large share in the coming years.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving healthcare facilities & infrastructure; growing patient awareness levels about available treatments; increasing medical tourism due to affordable cost of procedures & medicines; and government initiatives that enable free trade agreements with developed countries for enabling better access to quality health care services. These aforementioned factors are expected favorably impact overall revenue generation from 2018 through 2030 in this region of the world.
Major players operating in this industry include but not limited too: Johnson & Johnson Services Inc.; Allergan PLC.
Growth Factors:
- Increasing incidence of peripheral neuritis
- Growing awareness about peripheral neuritis and its treatment options
- Rising demand for better and more effective treatments for peripheral neuritis
- Technological advancements in the field of peripheral neuritis treatment 5. Growing number of clinical studies on new therapies for peripheral neuritis
Scope Of The Report
Report Attributes
Report Details
Report Title
Peripheral Neuritis Treatment Market Research Report
By Type
Diabetic Peripheral Neuropathy (DPN), Chemotherapy-induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy (IPN), Others, Peripheral Neuritis Treatmen
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Depomed, Novartis, Biogen, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Bristol-Myers Squibb, Baxter Healthcare, Johnson & Johnson, Teva Pharmaceuticals, Peripheral Neuritis Treatmen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Peripheral Neuritis Treatment Market Report Segments:
The global Peripheral Neuritis Treatment market is segmented on the basis of:
Types
Diabetic Peripheral Neuropathy (DPN), Chemotherapy-induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy (IPN), Others, Peripheral Neuritis Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Depomed
- Novartis
- Biogen
- GlaxoSmithKline
- Sanofi
- Eli Lilly and Company
- Bristol-Myers Squibb
- Baxter Healthcare
- Johnson & Johnson
- Teva Pharmaceuticals
- Peripheral Neuritis Treatmen
Highlights of The Peripheral Neuritis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diabetic Peripheral Neuropathy (DPN)
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Idiopathic Peripheral Neuropathy (IPN)
- Others
- Peripheral Neuritis Treatmen
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Peripheral Neuritis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Peripheral neuritis is a condition that affects the nerves that run outside of the brain and spinal cord. Symptoms can include pain, tingling, numbness, and weakness in one or more limbs. Treatment typically includes rest and medication to relieve symptoms.
Some of the key players operating in the peripheral neuritis treatment market are Pfizer, Depomed, Novartis, Biogen, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Bristol-Myers Squibb, Baxter Healthcare, Johnson & Johnson, Teva Pharmaceuticals, Peripheral Neuritis Treatmen.
The peripheral neuritis treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Peripheral Neuritis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Peripheral Neuritis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Peripheral Neuritis Treatment Market - Supply Chain
4.5. Global Peripheral Neuritis Treatment Market Forecast
4.5.1. Peripheral Neuritis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Peripheral Neuritis Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Peripheral Neuritis Treatment Market Absolute $ Opportunity
5. Global Peripheral Neuritis Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Peripheral Neuritis Treatment Market Size and Volume Forecast by Type
5.3.1. Diabetic Peripheral Neuropathy (DPN)
5.3.2. Chemotherapy-induced Peripheral Neuropathy (CIPN)
5.3.3. Idiopathic Peripheral Neuropathy (IPN)
5.3.4. Others
5.3.5. Peripheral Neuritis Treatmen
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Peripheral Neuritis Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Peripheral Neuritis Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Peripheral Neuritis Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Peripheral Neuritis Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Peripheral Neuritis Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Peripheral Neuritis Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Peripheral Neuritis Treatment Demand Share Forecast, 2019-2026
9. North America Peripheral Neuritis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Peripheral Neuritis Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Peripheral Neuritis Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Peripheral Neuritis Treatment Market Size and Volume Forecast by Type
9.7.1. Diabetic Peripheral Neuropathy (DPN)
9.7.2. Chemotherapy-induced Peripheral Neuropathy (CIPN)
9.7.3. Idiopathic Peripheral Neuropathy (IPN)
9.7.4. Others
9.7.5. Peripheral Neuritis Treatmen
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Peripheral Neuritis Treatment Demand Share Forecast, 2019-2026
10. Latin America Peripheral Neuritis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Peripheral Neuritis Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Peripheral Neuritis Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Peripheral Neuritis Treatment Market Size and Volume Forecast by Type
10.7.1. Diabetic Peripheral Neuropathy (DPN)
10.7.2. Chemotherapy-induced Peripheral Neuropathy (CIPN)
10.7.3. Idiopathic Peripheral Neuropathy (IPN)
10.7.4. Others
10.7.5. Peripheral Neuritis Treatmen
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Peripheral Neuritis Treatment Demand Share Forecast, 2019-2026
11. Europe Peripheral Neuritis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Peripheral Neuritis Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Peripheral Neuritis Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Peripheral Neuritis Treatment Market Size and Volume Forecast by Type
11.7.1. Diabetic Peripheral Neuropathy (DPN)
11.7.2. Chemotherapy-induced Perpheral Neuropathy (CIPN)
11.7.3. Idiopathic Peripheral Neuropathy (IPN)
11.7.4. Others
11.7.5. Peripheral Neuritis Treatmen
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Peripheral Neuritis Treatment Demand Share, 2019-2026
12. Asia Pacific Peripheral Neuritis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Peripheral Neuritis Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Peripheral Neuritis Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Peripheral Neuritis Treatment Market Size and Volume Forecast by Type
12.7.1. Diabetic Peripheral Neuropathy (DPN)
12.7.2. Chemotherapy-induced Peripheral Neuropathy (CIPN)
12.7.3. Idiopathic Peripheral Neuropathy (IPN)
12.7.4. Others
12.7.5. Peripheral Neuritis Treatmen
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Peripheral Neuritis Treatment Demand Share, 2019-2026
13. Middle East & Africa Peripheral Neuritis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Peripheral Neuritis Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Peripheral Neuritis Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Peripheral Neuritis Treatment Market Size and Volume Forecast by Type
13.7.1. Diabetic Peripheral Neuropathy (DPN)
13.7.2. Chemotherapy-induced Peripheral Neuropathy (CIPN)
13.7.3. Idiopathic Peripheral Neuropathy (IPN)
13.7.4. Others
13.7.5. Peripheral Neuritis Treatmen
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Peripheral Neuritis Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Peripheral Neuritis Treatment Market: Market Share Analysis
14.2. Peripheral Neuritis Treatment Distributors and Customers
14.3. Peripheral Neuritis Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Depomed
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Biogen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Eli Lilly and Company
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bristol-Myers Squibb
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Baxter Healthcare
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Johnson & Johnson
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Teva Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Peripheral Neuritis Treatmen
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
